But now the business is coming less than fire for a thing that simply can not be argued.

‘These sufferers have limited treatment options. Addressing this unmet medical need is a very high concern for our company, and also our investigators. O’Connor commented, ‘Although treatment using heat sensitive liposomal doxorubicin with microwave hyperthermia is investigational at the moment, we are motivated that this approach might provide a promising result for breast cancer sufferers with unpleasant loco-regional recurrence on the upper body wall. Nicholas Borys, Chief Medical Officer at Celsion Corporation commented, ‘We hope that by providing these updated clinical outcomes, perhaps even more leaders in rays oncology community will consider the DIGNITY Research for their patient’s with recurrent upper body wall tumor.’..GEN’s unique information and technology focus includes the complete bioproduct life cycle from early-stage R&D, to applied study including omics, biomarkers, along with diagnostics, to commercialization and bioprocessing.. Aeterna Zentaris to provide AEZS-108 Phase 2 results for endometrial tumor at EORTC-NCI-AACR Symposium Aeterna Zentaris Inc. AEZS-108, a novel hybrid molecule made up of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, can be in a Phase 2 trial in advanced endometrial. For more information on the trial, go to AEZS-108 may be the first intravenous drug in a clinical research that directs the chemotherapy agent specifically to luteinizing hormone-releasing hormone -receptor expressing tumors, resulting in even more targeted treatment with less harm to healthy tissue.